110 related articles for article (PubMed ID: 11701973)
1. CD8+ lymphocytes in the blister fluid of severe acute cutaneous graft-versus-host disease: further similarities with toxic epidermal necrolysis.
Correia O; Delgado L; Barbosa IL; Domingues JC; Azevedo R; Vaz CP; Pimentel P
Dermatology; 2001; 203(3):212-6. PubMed ID: 11701973
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical markers for histopathological diagnosis and differentiation of acute cutaneous graft-versus-host disease.
Wegner J; Weidenthaler-Barth B; Engelbert J; Knothe M; Braun C; Helbig D; Sacher C; Kreft A; Wagner EM; Ziemer M; Meyer RG; von Stebut E
Exp Dermatol; 2021 Dec; 30(12):1814-1819. PubMed ID: 34223669
[TBL] [Abstract][Full Text] [Related]
3. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis.
Correia O; Delgado L; Barbosa IL; Campilho F; Fleming-Torrinha J
J Am Acad Dermatol; 2002 Jul; 47(1):58-62. PubMed ID: 12077582
[TBL] [Abstract][Full Text] [Related]
4. Delayed presentation of toxic epidermal necrolysis-like cutaneous acute graft-versus-host disease in the setting of recent immunosuppressant discontinuation.
Goyal PKK; Xu S; Choi J
Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469783
[TBL] [Abstract][Full Text] [Related]
5. Toxic epidermal necrolysis possibly linked to hyperacute graft-versus-host disease after allogeneic bone marrow transplantation.
Takeda H; Mitsuhashi Y; Kondo S; Kato Y; Tajima K
J Dermatol; 1997 Oct; 24(10):635-41. PubMed ID: 9375462
[TBL] [Abstract][Full Text] [Related]
6. Acute blistering diseases on the burn ward: Beyond Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Richer V; Bouffard D; Bélisle A; Duranceau L; Perreault I; Provost N
Burns; 2013 Sep; 39(6):1290-6. PubMed ID: 23597847
[TBL] [Abstract][Full Text] [Related]
7. Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples.
Correia O; Delgado L; Roujeau JC; Le Cleach L; Fleming-Torrinha JA
Arch Dermatol; 2002 Jan; 138(1):29-32. PubMed ID: 11790164
[TBL] [Abstract][Full Text] [Related]
8. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors.
Le Cleach L; Delaire S; Boumsell L; Bagot M; Bourgault-Villada I; Bensussan A; Roujeau JC
Clin Exp Immunol; 2000 Jan; 119(1):225-30. PubMed ID: 10606987
[TBL] [Abstract][Full Text] [Related]
9. A pilot study comparing histological and immunophenotypic patterns in stage 4 skin graft vs host disease from toxic epidermal necrolysis.
Naik H; Lockwood S; Saavedra A
J Cutan Pathol; 2017 Oct; 44(10):857-860. PubMed ID: 28626936
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-host disease or toxic epidermal necrolysis: diagnostic dilemma after liver transplantation.
Jeanmonod P; Hubbuch M; Grünhage F; Meiser A; Rass K; Schilling MK; Kollmar O
Transpl Infect Dis; 2012 Aug; 14(4):422-6. PubMed ID: 22650490
[TBL] [Abstract][Full Text] [Related]
11. Extensive toxic epidermal necrolysis versus acute graft versus host disease after allogenic hematopoietic stem-cell transplantation: challenges in diagnosis and management.
Macedo FI; Faris J; Lum LG; Gabali A; Uberti JP; Ratanatharathorn V; White MT
J Burn Care Res; 2014; 35(6):e431-5. PubMed ID: 24476990
[TBL] [Abstract][Full Text] [Related]
12. A clinical and histological comparison between acute cutaneous graft-versus-host disease and other maculopapular eruptions following hematopoietic stem cell transplantation: a retrospective cohort.
Chanprapaph K; Leerunyakul K; Niparuck P; Rutnin S
Int J Dermatol; 2021 Jan; 60(1):60-69. PubMed ID: 32989780
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement.
Correia O; Delgado L; Ramos JP; Resende C; Torrinha JA
Arch Dermatol; 1993 Apr; 129(4):466-8. PubMed ID: 8466217
[TBL] [Abstract][Full Text] [Related]
14. Exanthema and enanthema in graft versus host disease (GVHD).
Suzuki M; Kikkawa Y; Hasegawa T; Kaneko F
Fukushima J Med Sci; 1993 Dec; 39(2):101-7. PubMed ID: 7927132
[TBL] [Abstract][Full Text] [Related]
15. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
[TBL] [Abstract][Full Text] [Related]
16. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis.
Nassif A; Bensussan A; Dorothée G; Mami-Chouaib F; Bachot N; Bagot M; Boumsell L; Roujeau JC
J Invest Dermatol; 2002 Apr; 118(4):728-33. PubMed ID: 11918724
[TBL] [Abstract][Full Text] [Related]
17. Marked increase of CD8+S6F1+ and CD8+CD57+ cells in patients with graft-versus-host disease after allogeneic bone marrow transplantation.
Fukuda H; Nakamura H; Tominaga N; Teshima H; Hiraoka A; Shibata H; Masaoka T
Bone Marrow Transplant; 1994 Feb; 13(2):181-5. PubMed ID: 7515741
[TBL] [Abstract][Full Text] [Related]
18. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.
Schwartz RA; McDonough PH; Lee BW
J Am Acad Dermatol; 2013 Aug; 69(2):187.e1-16; quiz 203-4. PubMed ID: 23866879
[TBL] [Abstract][Full Text] [Related]
19. Variable levels of apoptotic signal-associated cytokines in the disease course of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Yang Y; Li F; Du J; Shen Y; Lin J; Zhu X; Luo X; Liang J; Xu J
Australas J Dermatol; 2017 Aug; 58(3):e61-e67. PubMed ID: 27040133
[TBL] [Abstract][Full Text] [Related]
20. Toxic epidermal necrolysis versus cutaneous Graft-Versus-Host Disease in a hematopoietic stem cell transplant recipient: the role of elafin.
Chen A; Chao K; Rodriguez L; Munday W; Worswick S
Leuk Lymphoma; 2018 Sep; 59(9):2261-2263. PubMed ID: 29322835
[No Abstract] [Full Text] [Related]
[Next] [New Search]
